These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34597861)

  • 1. The success rate of online illicit drug transactions during a global pandemic.
    Bergeron A; Décary-Hétu D; Giommoni L; Villeneuve-Dubuc MP
    Int J Drug Policy; 2022 Jan; 99():103452. PubMed ID: 34597861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary findings of the impact of COVID-19 on drugs crypto markets.
    Bergeron A; Décary-Hétu D; Giommoni L
    Int J Drug Policy; 2020 Sep; 83():102870. PubMed ID: 32741719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safer scoring? Cryptomarkets, social supply and drug market violence.
    Barratt MJ; Ferris JA; Winstock AR
    Int J Drug Policy; 2016 Sep; 35():24-31. PubMed ID: 27241015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No magic pocket: Buying and selling on drug cryptomarkets in response to the COVID-19 pandemic and social restrictions.
    Barratt MJ; Aldridge J
    Int J Drug Policy; 2020 Sep; 83():102894. PubMed ID: 32741717
    [No Abstract]   [Full Text] [Related]  

  • 5. Illicit drug prices and quantity discounts: A comparison between a cryptomarket, social media, and police data.
    Moeller K; Munksgaard R; Demant J
    Int J Drug Policy; 2021 May; 91():102969. PubMed ID: 33041184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing market competition and vendors' size and scope on AlphaBay.
    Paquet-Clouston M; Décary-Hétu D; Morselli C
    Int J Drug Policy; 2018 Apr; 54():87-98. PubMed ID: 29414490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hidden wholesale: The drug diffusing capacity of online drug cryptomarkets.
    Aldridge J; Décary-Hétu D
    Int J Drug Policy; 2016 Sep; 35():7-15. PubMed ID: 27260863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between cryptomarket drug purchase, social networks and adverse drug events: A cross-sectional study.
    Coney L; Peacock A; Malm A; Munksgaard R; Aldridge J; Ferris JA; Maier LJ; Winstock AR; Barratt MJ
    Int J Drug Policy; 2024 Jan; 123():104258. PubMed ID: 38056221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivery dilemmas: How drug cryptomarket users identify and seek to reduce their risk of detection by law enforcement.
    Aldridge J; Askew R
    Int J Drug Policy; 2017 Mar; 41():101-109. PubMed ID: 28089207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should we smoke it for you as well? An ethnographic analysis of a drug cryptomarket environment.
    Kowalski M; Hooker C; Barratt MJ
    Int J Drug Policy; 2019 Nov; 73():245-254. PubMed ID: 31054880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing cryptomarkets for drugs. A characterisation of sellers and buyers over time.
    Tzanetakis M
    Int J Drug Policy; 2018 Jun; 56():176-186. PubMed ID: 29449105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reputation transferability across contexts: Maintaining cooperation among anonymous cryptomarket actors when moving between markets.
    Norbutas L; Ruiter S; Corten R
    Int J Drug Policy; 2020 Feb; 76():102635. PubMed ID: 31972474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Will growth in cryptomarket drug buying increase the harms of illicit drugs?
    Aldridge J; Stevens A; Barratt MJ
    Addiction; 2018 May; 113(5):789-796. PubMed ID: 28766792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Offline constraints in online drug marketplaces: An exploratory analysis of a cryptomarket trade network.
    Norbutas L
    Int J Drug Policy; 2018 Jun; 56():92-100. PubMed ID: 29621742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'Nice people doing shady things': Drugs and the morality of exchange in the darknet cryptomarkets.
    Masson K; Bancroft A
    Int J Drug Policy; 2018 Aug; 58():78-84. PubMed ID: 29870962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Psychoactive Substances and receding COVID-19 pandemic: really going back to "normal"?
    Napoletano S; Basile G; Lo Faro AF; Negro F
    Acta Biomed; 2022 May; 93(2):e2022186. PubMed ID: 35545997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Forensic drug intelligence and the rise of cryptomarkets. Part II: Combination of data from the physical and virtual markets.
    Morelato M; Broséus J; De Grazia A; Tahtouh M; Esseiva P; Roux C
    Forensic Sci Int; 2018 Jul; 288():201-210. PubMed ID: 29763810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An island apart? Risks and prices in the Australian cryptomarket drug trade.
    Cunliffe J; Martin J; Décary-Hétu D; Aldridge J
    Int J Drug Policy; 2017 Dec; 50():64-73. PubMed ID: 29055855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Going international? Risk taking by cryptomarket drug vendors.
    Décary-Hétu D; Paquet-Clouston M; Aldridge J
    Int J Drug Policy; 2016 Sep; 35():69-76. PubMed ID: 27453145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonmedical prescription psychiatric drug use and the darknet: A cryptomarket analysis.
    Cunliffe J; Décary-Hêtu D; Pollak TA
    Int J Drug Policy; 2019 Nov; 73():263-272. PubMed ID: 30772109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.